Cycle guidelines Cycle guidelines Approach Phase 2 reference Duration 48 weeks Review Point Every 4 weeks at each dose step Best For Matches the original NEJM trial structure Approach Phase 3 TRIUMPH reference Duration 68-72 weeks Review Point Every 4 weeks
After 30 days on the 3 mg dosage, your healthcare provider may have you increase your dosage to 7 mg
GLP-1 for sleep apnea, alcohol use and cancer risk GLP-1s may address conditions well beyond metabolic diseases: Obstructive sleep apnea: Emerging data suggest GLP-1s improve apnea symptoms. Alcohol use disorder: Patients using liraglutide or semaglutide reduced alcohol consumption by nearly two-thirds. Obesity-related cancers: An observational study of 6,000 adults found that GLP-1 receptor agonists halved the risk of obesity-related cancers compared with usual care
This product is intended only for qualified research environments and should be handled according to appropriate laboratory procedures
Tirzepatide shows promising hepatic effects in ongoing MASLD trials, and semaglutide has demonstrated modest liver fat reduction, but neither approaches the retatrutide benchmark
Learn evidence-based timing, portion control advice, and how GLP-1 supports sustained weight loss after surgery
